APPLICATION BULLETIN IMPROVED CHEMICAL RESISTANCE Engineered polyketone delivers excellent performance against aggressive chemicals, like H2SO4 for batteries (Figure 1), and performs similarly to nylon against typical chemicals tested in powersports, such as gasoline* (Figure 2). Gasoline - 30% glass-filled (GF) grade, dry as molded (DAM), room temperature Testing methodology is an adaptation from ASTM D543 • Reapply freshly soaked gauze pad every 24 hours to prevent from drying out • Repeat for a total of 72 hours • Tensile properties recorded *Chemical resistance data for DEET, motor oil, glass cleaner, and sunscreen available upon request KEY CHARACTERISTICS Figure 1 Figure 2 3.34 3.84 3.63 1.96 2.21 0.99 3.43 3.86 3.93 1.76 3.49 2.01 3.26 3.66 3.74 1.45 1.06 0.989 2.98 3.99 3.41 1.41 1.07 0.88 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 30% LGF PKE 30% LGF PA6 30% LGF PA66 30% SGF PKE 30% SGF PA6 30% SGF PA66 Ft -lb /in Notched Izod Impact ASTM D256 23C DAM 23C Conditioned -40C DAM -40C Conditioned 1.47 1.37 1.37 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 Glass-Filled PKE Glass-Filled PA6 Glass-Filled PA66 g/ cm 3 Density of Polyketone vs Nylon ASTM D792 LESS MOISTURE ABSORPTION THAN NYLON 30% Short Glass Fiber (SGF) Comparison Moisture uptake, environmental chamber 62% RH, 70°C SIMILAR DENSITY TO NYLON ASTM D792 COMPARABLE AND CONSISTENT IMPACT PERFORMANCE* Notched Izod Impact (ASTM D256) of LGF and SGF for DAM and Conditioned Materials *3,000 hr weathering data available upon request KEY CHARACTERISTICS 1.844.4AVIENT www.avient.com Copyright © 2024, Avient Corporation.

Eastern Time on July 30, 2021. 3 *Pro Forma The company acquired the Clariant Masterbatch business (“CMB”) on July 1, 2020 (the “Acquisition Date”). To access, dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and provide conference ID number 2587092. See Attachment 3 for a definition and summary of special items.

По этой причине избегайте ненужных контактов с конкурентами. 3. Избегайте даже видимости такого рода соглашений, а также ситуаций, в которых они могут возникнуть. 3. Запрещается иным образом получать информацию (в частности, о цене) непосредственно от конкурентов. 4.

Aktualizováno: únor 2021 Globální antimonopolní zásady společnosti Avient Obsah Přehled zásad 1 Een Overzicht van de Amerikaanse Přehled antimonopolních zákonů USA 1 Porušení antimonopolních zákonů 3 Oblasti potenciálně dotčené antimonopolní problematikou 3 Závěr 5 Hlášení možných porušení 6 Horká linka pro etiku společnosti Avient 6 Ochrana před odvetou 6 Antimonopolní kontrolní seznam 7 Rychlé rady: Antimonopolní zásady CO DĚLAT a CO NEDĚLAT 9 Návod k dodržování předpisů Společnost Avient se zavázala podporovat spravedlivou hospodářskou soutěž a svobodné podnikání na trhu. Vyhněte se i pouhému zdání takové dohody a vyhněte se situacím, kdy by takové dohody mohly nastat. 3. Nesnažte se žádným způsobem získat přímo od konkurentů informace (zejména o cenách). 4.

Notificación desde Registro HUESCA 2 MERC PLAZA CONCEPCION ARENAL,3 2º A 22002 - HUESCA NOTIFICACIÓN DE INSCRIPCIÓN TOTAL Se pone en su conocimiento que el documento del día veinticinco de enero de dos mil veintidós, que fue presentado el día veintisiete de enero de dos mil veintidós, con el número de entrada 1/2022/233,0, diario 46, asiento 131, ha sido inscrito con fecha diecisiete de febrero de dos mil veintidós, en el tomo 661, folio 67, inscripción 5 con hoja HU-13568, de la entidad AVIENT SÀ RL SUCURSAL EN ESPAÑA. HUESCA 2 MERC PLAZA CONCEPCION ARENAL,3 2º A 22002 - HUESCA Este documento ha sido firmado con firma electrónica reconocida por Dña. Art. 27.3 de la Ley 39/2015, de 1 de octubre, del Procedimiento Administrativo Común de las Administraciones Públicas.).

To access, dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and provide conference ID number 7899765. See Attachment 3 for a definition and summary of special items. See Attachment 3 for a definition and summary of special items.

Clause 1, Clause 2, Clause 3, Clause 6, Clause 7; ii. Clause 4 Interpretation a. Clause 1, Clause 2, Clause 3, Clause 6, Clause 7; ii.

Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation Page 4 • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth • 17 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Steve Newlin Appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2013 2014 and beyond -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $38.38 March 7th, 2014 • 17 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 5 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% United States 66% Europe 14% Canada 7% Asia 6% Latin America 7% PP&S 20% Specialty 53% Distribution 27% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target A dj us te d Ea rn in gs P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 6 PolyOne At A Glance Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 2015 % o f O pe ra ti ng In co m e* JV's Performance Products & Solutions Distribution Specialty Specialty OI $5M $46M $87M $195M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 2013 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.2% 12 – 16% Global Specialty Engineered Materials 1.1% 9.3% 12 – 16% Designed Structures & Solutions -- 5.6% 8 – 10% Performance Products & Solutions 5.4% 7.2% 9 – 12% Distribution 2.6% 5.9% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.1% 15% 4) Adjusted EPS Growth N/A 31% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 Bridge To $2.50 Adjusted EPS By 2015 2015 EPS: $2.50 2013 EPS: $1.31 Mid single digit revenue CAGR Page 9 Mergers & Acquisitions Spartech accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 10 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 11 Unique and Innovative Solutions that Help Customers Win https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG Net Debt / EBITDA* = 1.8x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Significant Debt Maturities As of December 31, 2013 ($ millions) Page 12 Coupon Rates: 7.500% 7.375% 5.250% Debt Maturities & Pension Funding – 12/31/13 *TTM 12/31/2013 ** includes US-qualified plans only 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2013 Pension Funding** As of December 31, 2013 Free Cash Flow and Strong Balance Sheet Fund Investment • Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin • Synergy opportunities • Adjacent material solutions • Expanding our sales, marketing, and technical capabilities • Investing in operational and LSS initiatives (including synergy capture) • Manufacturing alignment Organic Growth Share Repurchases Dividends Acquisitions Page 13 $0.16 $0.20 $0.24 $0.32 $0.00 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend • Repurchased ~5 million shares in 2013 • 15 million shares are available for repurchase under the current authorization The New PolyOne: A Specialty Growth Company 2015 Target: $2.50 Adjusted EPS Why Invest In PolyOne? Strong past performance demonstrates that our strategy and execution are working • Megatrends align with our strengths • Innovation and services provide differentiation, incremental pricing power, and competitive advantage • Strong and proven management team driving growth and performance • Addressable market exceeds $40 billion Page 14 1 Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. Gabelli Non-GAAP.pdf Section 1

STAN-TONE MB- PINK 9/3 X HC 134121#SR-13030 Red X HC 134121#SR-13031 Grey

KEY CHARACTERISTICS • Manufactured under change control principles beyond CAS number (similar level as MEVOPUR concentrates), reducing risk of change • Free from animal-derived substances and phthalates • Suitable for blown film, injection molding, blow molding and extrusion REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP chapters , including Class VI, a requirement for ophthalmic and nasal drugs - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities - USP and USP light transmission • Registered Drug Master File (Type III) • Food contact compliance established with FDA/EU* APPLICATION BULLETIN CARRIER MATERIAL PIGMENT CONTENT/TYPE LIGHT FASTNESS THERMAL STABILITY PRODUCT CODE HDPE 50% TiO2 8 300°C PH00075525 LLDPE 60% TiO2 8 300°C PL00075542 LLDPE 70% TiO2 8 300°C PL00075545 PP 50% TiO2 8 300°C PP00075717 Healthcare use limitations apply—see below. Without limiting the generality of this statement, Avient products shall not be used in any medical device application intended for: (1) exposure to human tissue or body fluids for 30 days or greater; (2) “plastic” (cosmetic or reconstructive) surgery use; (3) reproductive implants or any birth control device; or (4) any critical component in a permanently (greater than 30 days) implanted medical device that supports or sustains human life.